23. Dhainaut JF, Laterre PF, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients and septic shock, N Eng J Med
24. Dodds Aw, Sim Rb. Complement. A practical approach. IRL Press, 1997.
25. Dunzer MW, Mayr AJ, Ulmer H et al. Arginine Vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107: 2313-19.
26. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J and ANZICS Clinical Trials Group Sepsis Investigators. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589-596.
27. Gao F, Melody T, Daniels DF, Giles S, Fox S. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care 2005; 9: 764-770
28. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-140.
29. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490-1497.
30. Harbeck Rj, Giclas Pc. Diagnostic immunology laboratory manual. Nueva York, Raven Press, 1991.
31. Harrison LH, Ali A, Dwyer DM, Libonati JP, Reeves MW, Elliot JA, et al.
32. Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent JL, Zanotti-Cavazzoni S. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32: 1928-1948.
33. Hollenberg SM, Ahrens TS, Annane D, et al Practica parameters for hemodynamic support of sepsis in adult patients, 2004 update Crit Care Med 2004; 32: 0928-48.
34. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: A modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13:606-608.

35. Kortgen A, Niederprum P, Bauer M. Implementation of an evidence-based “standard operating procedure” and outcome in septic shock. Crit Care Med 2006; 34: 943-949.
36. Kortgen A, Niederprum P, Bauer M.. Implementation of an evidence-based“standard operating procedure” and outcome in septic shock. Crit Care Med 2006; 34: 943-949.
37. Law SKA, Reid KBM. Complement. Londres, IRL Press, 1996.
38. Levi M, Cate HT, Poll T, Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270:975-979.
39. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference. 2001 SCCM/ ESICM/ ACCP/ ATS/ SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-538.
40. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, Williams MD. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005; 33: 2194-2201.
41. Lizzewski M, Farries T, Lublin I, Rooney I, Atkinson J. Control of the Complement System. Adv Immunol 1996; 61:201-257.
42. Makrides S. Therapeutic Inhibition of the Complement System. Pharmacol Rev 1998; 50:59-87.
43. Mallolas J, Gatell JM, Miró JM, Marco F, Bisbe J, Jiménez De Anta MT et al. Analysis of prognosis factors in 274 consecutive episodes of Pseudomonas aeruginosa bacteremia. En: Homma JY, Tanimoto H, Holder IA, Hoiby N, Doring G, eds. Pseudomonas aeruginosa in human diseases. Antibiot Chemother 1991; 44:106-114.
44. Marx J. Rosen´s Emergency Medicine: Concepts and Clinical Practice. 5th ed St. Louis Mo.: Mosby; 2002: 1957
45. Mayhall CG, ed. Hospital epidemiology and infection control. Baltimore, Williams and Wilkins, 1996.
46. Morgan Bp. Complement. Clinical aspects and relevance to disease. Nueva York, Academic Press, 1990.
47. Moss M, Martin GS. A global perspective on the epidemiology of sepsis. Intensive Care Med 2004; 30: 527-529.
48. Muñoz P, Coque T, Rodríguez-Créixems M, Bernaldo de Quirós JCL, Moreno S, Bouza E. Group B Streptococcus: A cause of urinary tract infection in nonpregnant adults. Clin Infect Dis 1992; 14:492-496.
49. Muñoz P, Llancaqueo A, Rodríguez-Créixems M, Peláez T, Martín L, Bouza E. Group B Streptococcus bacteremia in nonpregnant adults. Arch Intern Med 1997; 157:213-216.
50. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hours in intensive care units in England, Wales and Northern Ireland. Crit Care Med 2003; 31: 2332-2338.
51. Palencia E. Epidemiología de la sepsis REMI 2004: 4 (7): C 1b
52. Palencia E. Epidemiología de la sepsis REMI 2004: 4 (7); 1b
53. Palencia E. Tratamiento del enfermo con sepsis grave REMI: 2005:5 (3): C3
54. Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatr Infect Dis J 1993; 12:268-274.
55. Porcel-Pérez Jm, ed. El sistema del complemento: de la inmunología a la clínica. Rev Clin Esp 1996; 196 (monografía 1).
56. Pronovost PJ, Nolan T, Zeger S, Miller M, Rubin H. How can clinicians measure safety and quality in acute care?. Lancet 2004; 363: 1061-1067.
57. Rakel P, ed Conn´s Current Therapy 2005 57th ed Philadelphia, Pa WB Saunders 2005:71
58. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med 1995; 123:421-427.
59. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early goal-directed therapy in the treatment of severe sepsis and septic shock, N Eng J Med 2001; 345; 1368-1377.
60. Rivers EP. Early Goal-Directed Therapy in severe sepsis and septic shock. Converting science to reality. Chest 2006; 129: 217-218.
61. Rolston KV, Boded GP. Pseudomonas aeruginosa infection in cancer patients. Cancer Invest 1992; 10:43-59.
62. Rosselló J, Trilla A. Epidemiología de las infecciones nosocomiales. Todo Hospital 1995; 114:21-28.
63. Rother K, Till Go, Hänsch Gm. The complement system. Nueva York, Springer, 1997.
64. Rudis MI, Basha MA, Zarowitz BJ. Is it time to reposition vasopressors and inotropes in sepsis? Crit Care Med 1996; 24:525-537.
65. Shapiro NI, Howell MD, Talmor D, Lahey D, Ngo L, Buras J, Wolfe RE, Weiss JW, Lisbon A. Implementation and outcomes of the multiple urgent sepsis therapies (MUST) protocol. Crit Care Med 2006; 34: 1025-1032.
66. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 2005; 94: 1176-1186.
67. Silva E, de Almeida M, Beltrami AC, et al. Brazilian sepsis epidemiologic study (BASES study). Crit Care 2004, 8: R251-R260.
68. Sprung CL, Sakr Y, Vincent JL, Le Gall JR, Reinhart K, Ranieri VM, Gerlach H, Fielden J, Groba CB, Payen D. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely Ill Patients (SOAP study). Intensive Care Med 2006; 32: 421-427.
69. Stevens DL, Tanner MH, Winship J. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-6.
70. Surviving Sepsis Campaign. http://www.survivingsepsis.org
71. Surviving Sepsis Campaign: Position Paper
72. Torrabadella de Reynoso P, Salgado Remigio A. Nuevos tratamientos de la sepsis grave. Una encrucijada científica, económica y ética. Med Clin (Barc) 1999; 113:18-19.
73. Torrabadella de Reynoso P, Salgado Remigio A. Óxido nítrico y sus inhibidores en la sepsis y el shock séptico. Med Intensiva 1993; 17: 477-484.
74. Trilla A, Vaqué J, Sallés M, Jiménez de Anta MT, Asenjo MA. Prevention and control of nosocomial infections in Spain. Infect Control Hosp Epidemiol 1996; 17:617-622.
75. Trilla A. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 1994; 20 (S3):1-5.
76. Trzeciak S, Dellinger RP, Abate NL, Cowan RM, Stauss M, Kilgannon JH, Zanotti S, Parrillo JE.Translating research to clinical practice. A 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. Chest 2006; 129: 225-232.
77. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R, Intensive Insulin therapy in the medical ICU, N Engl J Med 2006, 354-461.
78. Vaqué J, Rosselló J, Trilla A, Monge V, García-Caballero J, Arribas JL et al. Nosocomial infections in Spain: Results of four nationwide serial prevalence surveys (EPINE Project, 1990-1993). Infect Control Hosp Epidemiol 1996; 17:293-297.
79. Verger G. Infección quirúrgica. En: Verger G, ed. Enfermedades infecciosas. Barcelona, Doyma, 1989; 603-607.
80. Verger G. Septicemias y bacteriemias. En: Verger G, ed. Enfermedades infecciosas. Barcelona, Doyma, 1989; 77-83.
81. Vila J, Marcos A, Marco F, Abdalla S, Vergara Y, Reig R et al. In vitro antimicrobial production of beta-lactamases, aminoglycosides-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1993; 37:138-141.
82. Vila J. Mechanisms of antimicrobial resistance in Acinetobacter baumannii. Rev Med Microbiol 1998; 9:87-97.
83. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-353.
84. Vivanco F, Casado Mt. Déficit congénitos del complemento y enfermedades reumáticas. Angioedema hereditario. Tratado de Reumatologia. Madrid, Ed. Arán, 1998.
85. Volanakis JE, Frank MM. The Human Complement System in Health and Disease. Nueva York, Marcel Dekker, 1998
86. Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. CID 1996; 23:406.
87. Wenzel RP, ed. Prevention and control of nosocomial infections, 3.a ed. Baltimore, Williams and Wilkins, 1997.
88. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207-214.
89. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, Linde-Zwirble W. Hospitalized patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004; 8: 291-298.
90. Zeni F, Freeman B, Natanson C. Antiinflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25:1095-1100.